TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03130413

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ambu Aura Gain supraglottic airway
Description: Anesthesia is induced with sevoflurane in oxygen. The anesthesia plane is gradually deepened by increasing the inspired concentration of sevoflurane (2-8%) till the loss of eyelash reflex. After intravenous (IV) cannula is inserted and intravenous fentanyl 1mcg/kg and rocuronium 0.6mg/kg are administered. Use of neuromuscular blocking agent is to minimize the risk of reflex activation of the airway. After 3 minutes, the appropriate size (depending upon body weight) of Ambu Aura Gain is lubricated with water soluble lubricant (KY jelly) is inserted by investigator based on manufacturer recommendation with the patient's head in neutral position. The cuff then is inflated to an intra-cuff pressure of 40 cm H20, measured using a digital cuff pressure monitor.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Air-Q supraglottic airway
Description: Anesthesia is induced with sevoflurane in oxygen. The anesthesia plane is gradually deepened by increasing the inspired concentration of sevoflurane (2-8%) till the loss of eyelash reflex. After intravenous (IV) cannula is inserted and intravenous fentanyl 1mcg/kg and rocuronium 0.6mg/kg are administered. Use of neuromuscular blocking agent is to minimize the risk of reflex activation of the airway. After 3 minutes, the appropriate size (depending upon body weight) of Air-Q supraglottic airway is lubricated with water soluble lubricant (KY jelly) is inserted by investigator based on manufacturer recommendation with the patient's head in neutral position. The cuff then is inflated to an intra-cuff pressure of 40 cm H20, measured using a digital cuff pressure monitor.
Study: NCT02330341

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Artemisia dracunculus

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02914327

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SNX-5422 plus ibrutinib
Description: SNX-5422 capsule(s) dosed every other day for 21 days out of a 28-day treatment cycle to a total dose of 56 mg/m2 SNX-5422. Subjects will self-administer daily oral ibrutinib in the afternoon at least 8 hours apart from SNX-5422 for 28 days of each cycle.
Study: NCT04120818

Intervention type: PROCEDURE
Intervention: secondary IOL implantation
Description: reopened the fibrotic, closed capsular bag and achieve IOL placement

Intervention type: PROCEDURE
Intervention: primary IOL implantation
Description: lensectomy and anterior vitrectomy and primary IOL implantation
Study: NCT00573924

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Proton pump inhibitor (lansoprazole)
Description: 1. 120 mg PO and then 30 mg PO q 3 h from 3 to 21 hrs~2. 90 mg IV bolus followed 9 mg/hr infusion for 24 hrs

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Proton pump inhibitor (lansoprazole)
Description: 1. 120 mg PO and then 30 mg PO q 3 h from 3 to 21 hrs~2. 90 mg IV bolus followed 9 mg/hr infusion for 24 hrs
Study: NCT03715062

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dialogue tool
Description: The intervention has two parts: an educational session and a dialogue tool. The educational session consists of 75 minutes of education in diagnosing urinary tract infection. The dialogue tool consists of 1) a checking box for the most important symptoms and observations for urinary tract infection 2) an algorithm to evaluate if urinary tract infection is likely based on the present symptoms and observations 3) a list of reflection points to evaluate with a collegue 4) a specialized ISBAR (communication tool) if long-term care facility staff finds it appropriate to contact the General Practicioner
Study: NCT03834350

Intervention type: OTHER
Group type: OTHER
Intervention: BREATHES Program
Description: Participants will complete inhaler education using the virtual education module at the baseline visit of the study. Additionally, they will be asked to complete the lesson at least once before their 30 day follow-up visit on their personal device once they have been discharged from the hospital. At the time of their initial study visit, study participants will be given a SpiroPD device for use at home following instruction in the hospital or clinic. Patient adherence to daily testing over one-month will be monitored using real-time capture Wi-Fi-data from the SpiroPD data portal. A small device will be attached to track real-time medication use.

Intervention type: DEVICE
Group type: OTHER
Intervention: BREATHES SpiroPD or Propeller Health
Description: At the time of their initial study visit, study participants may be given a SpiroPD device for use at home following instruction in the hospital or clinic. Patient adherence to daily testing over one-month will be monitored using real-time capture Wi-Fi-data from the SpiroPD data portal. A small device will be attached to track real-time medication use.
Study: NCT03188575

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SilverCloud Internet-delivered Cognitive Behavioural Therapy
Description: SilverCloud Health is a leading provider of online therapeutic solutions to support and promote positive behavior change and mental wellness. SilverCloud delivers interventions for all of the anxiety disorders (panic disorder, social anxiety, phobias, GAD, health anxiety, OCD), depression and also comorbid depression and anxiety. The programs for the treatment of depression and anxiety employ several innovative engagement strategies for improving the user experience. These are divided into several categories: personal, interactive, supportive, and social. Research on the SilverCloud interventions has yielded significant clinical outcomes (Richards et al., 2015).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Waiting List
Description: 8 week waiting list period.
Study: NCT04069117

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: letrozole 2.5mg (Femara; Novartis Pharma Services, Basel, Switzerland)
Description: letrozole /antagonist protocol
Study: NCT03203785

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Carbohydrate (maltodextrin)
Description: maltodextrin flavored

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: non-caloric drink
Study: NCT01092377

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: DHA and EPA Fish Oil capsule
Description: 2 DHA/EPA capsules on 4 days per week containing totally 420 mg DHA and 80 mg EPA, providing an average dose of 285.7 mg n-3 fatty acids per day

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: DHA and EPA Fish Oil capsule
Description: 2 DHA/EPA capsules on 4 days per week containing totally 420 mg DHA and 80 mg EPA, providing an average dose of 285.7 mg n-3 fatty acids per day

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Iron tablet
Description: 1 iron tablet containing 50 mg of iron as ferrous sulfate will be administered on 4 days per week, providing an average iron dose of 28.6 mg iron per day.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Iron tablet
Description: 1 iron tablet containing 50 mg of iron as ferrous sulfate will be administered on 4 days per week, providing an average iron dose of 28.6 mg iron per day.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo tablet
Description: Placebo tablet will be administered on 4 days per week and will be identical in appearance to the iron tablet.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablet
Description: Placebo tablet will be administered on 4 days per week and will be identical in appearance to the iron tablet.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo capsule
Description: Placebo capsules contain medium chain triglycerides and will be identical in appearance and total fat content to the DHA/EPA capsules.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsule
Description: Placebo capsules contain medium chain triglycerides and will be identical in appearance and total fat content to the DHA/EPA capsules.
Study: NCT03523286

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RAPID-VT Software guided ablation
Description: Catheter ablation will target VT exit sites at scar margin as determined by the RAPID-VT software
Study: NCT01603277

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-GM-CSF Monoclonal Antibody 400mg
Description: Anti-GM-CSF Monoclonal Antibody 400mg

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal Saline
Study: NCT01206764

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAD001
Study: NCT04228224

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robot-assisted training with a lower extremity powered exoskeleton (H3 Exoskeleton, Spain)
Description: The H3 is a powered lower extremity exoskeleton with actuated at hips, knees and ankles joints. A novel control software has been design and implemented in this device, which allows selective joint movement and recording of data from each rehabilitation session.
Study: NCT03182192

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: 68Ga-NODAGA-exendin-4 PET/CT
Description: 68Ga-NODAGA-exendin-4 PET/CT scan

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 68Ga-NODAGA-exendin-4 PET/CT
Description: 68Ga-NODAGA-exendin-4 PET/CT scan
Study: NCT04228224

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional gait rehabilitation
Description: Conventional gait rehabilitation consist in walking and other applicable lower limb exercises performed by participants with assistance of a physical therapist.
Study: NCT04435496

Intervention type: DEVICE
Group type: OTHER
Intervention: GYN-CS
Description: placement of the GYN-CS device
Study: NCT00496561

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: subcutaneous immunotherapy (House Dust Mites)
Description: subcutaneous immunotherapy (House Dust Mites)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo of subcutaneous immunotherapy (House Dust Mites)
Description: placebo of subcutaneous immunotherapy (House Dust Mites)
Study: NCT02506920

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Six different types of fat in a meal in random order
Description: Oral fat tolerance test

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Six different types of fat in a meal in random order
Description: Oral fat tolerance test

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Six different types of fat in a meal in random order
Description: Oral fat tolerance test

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Six different types of fat in a meal in random order
Description: Oral fat tolerance test

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Six different types of fat in a meal in random order
Description: Oral fat tolerance test

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Six different types of fat in a meal in random order
Description: Oral fat tolerance test
Study: NCT02636621

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Brazilian Dental Appliance
Description: Brazilian Dental Appliance is an oral appliance worn only during sleep that supports the jaw in a forward position to help maintain an open upper airway.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo consists in a protective dental plate worn only during sleep that do not interfere in the size of the upper airway.
Study: NCT05912868

Intervention type: DEVICE
Intervention: Endoscopic Mini/Less Open Sublay Repair
Description: The traditional techniques are open sublay or transabdominal intraperitoneal onlay mesh (IPOM) repair. In order to avoid the risks -large trauma to the abdominal wall with pain and infection, lesion of intraabdominal organs - a new hybrid technique - small skin incision, wide endoscopic dissection of the retrorectus space with implantation of a large mesh - was developed (EMILOS -Endoscopic Mini/Less Open Sublay).
Study: NCT01613924

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Split face: handheld acne heat based device (Zeno Hot Spot) and no treatment
Description: Subjects will apply the actual device to every inflammatory acne facial lesion on one half of the face and no treatment to every inflammatory acne lesion on the other half of the face at 6 hour intervals for a total of 3 treatments. Follow up will occur daily over a 5 day period.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Split face: handheld acne heat based device, Zeno Hot Spot, and topical benzoyl peroxide 4%
Description: Subjects will apply the actual device to every inflammatory acne facial lesion on one half of the face at 6 hour intervals for a total of 3 treatments. Subjects will apply benzoyl peroxide to the other half of the face daily for 5 days.
Study: NCT01900444

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMOJEV
Description: 0.5 mL, Subcutaneous
Study: NCT03423069

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Diet low in FODMAPs
Description: A strict restriction of all high FODMAP foods for the time of observation. All these foods will be identified by appropriate nutritional visits and alternatives will be suggested to ensure the diet is nutritionally adequate.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Specific dietary advice for IBS
Description: Dietary recommendations such as limitation of alcohol, spicy food and fatty foods, caffeine, carbonated drinks; avoidance of chewing gums and sweeteners containing polyols; small and frequent meals; avoidance of stressful conditions and eating slowly.
Study: NCT05720403

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pilates group
Description: Pilates, which lasts for eight weeks, three days a week for 1 hour, will be carried out by Australian Pilates and Physiotherapy Institute certified and experienced Ph.D. Physiotherapist Halil Ibrahim Bulguroglu. Microsoft Teams program will be used to implement the online practice method. The individuals in both pilates exercise groups will be divided into six small groups of 3 or 4 people to make the exercises more effective. In this study, the program will be 15 minutes of warm-up, 30 minutes of pilates, and 15 minutes of cool-down and stretching exercises. The exercises will be performed in ten repetitions. The same exercises will be applied in online pilates and face-to-face pilates training.
Study: NCT03094156

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 1 capsule of placebo \[to be taken orally, with 240 mL of potable water\]

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 6-512
Description: 1 capsule of BIA 6-512 25mg or 1 capsule of BIA 6-512 50 mg or 1 capsule of BIA 6-512 75 mg or 1 capsule of BIA 6-512 100 mg \[to be taken orally, with 240 mL of potable water\]

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 6-512
Description: 1 capsule of BIA 6-512 25mg or 1 capsule of BIA 6-512 50 mg or 1 capsule of BIA 6-512 75 mg or 1 capsule of BIA 6-512 100 mg \[to be taken orally, with 240 mL of potable water\]

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 6-512
Description: 1 capsule of BIA 6-512 25mg or 1 capsule of BIA 6-512 50 mg or 1 capsule of BIA 6-512 75 mg or 1 capsule of BIA 6-512 100 mg \[to be taken orally, with 240 mL of potable water\]

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 6-512
Description: 1 capsule of BIA 6-512 25mg or 1 capsule of BIA 6-512 50 mg or 1 capsule of BIA 6-512 75 mg or 1 capsule of BIA 6-512 100 mg \[to be taken orally, with 240 mL of potable water\]

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Madopar® 250
Description: Levodopa/benserazide immediate release tablets 200mg/50mg \[to be taken orally, with 240 mL of potable water\]

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Madopar® 250
Description: Levodopa/benserazide immediate release tablets 200mg/50mg \[to be taken orally, with 240 mL of potable water\]

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Madopar® 250
Description: Levodopa/benserazide immediate release tablets 200mg/50mg \[to be taken orally, with 240 mL of potable water\]

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Madopar® 250
Description: Levodopa/benserazide immediate release tablets 200mg/50mg \[to be taken orally, with 240 mL of potable water\]

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Madopar® 250
Description: Levodopa/benserazide immediate release tablets 200mg/50mg \[to be taken orally, with 240 mL of potable water\]

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comtan®
Description: Entacapone 200 mg tablets \[to be taken orally, with 240 mL of potable water\]

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comtan®
Description: Entacapone 200 mg tablets \[to be taken orally, with 240 mL of potable water\]

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comtan®
Description: Entacapone 200 mg tablets \[to be taken orally, with 240 mL of potable water\]

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comtan®
Description: Entacapone 200 mg tablets \[to be taken orally, with 240 mL of potable water\]

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comtan®
Description: Entacapone 200 mg tablets \[to be taken orally, with 240 mL of potable water\]
Study: NCT02734134

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: One-stage exchange joint replacement surgery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Two-stage exchange joint replacement surgery
Study: NCT00577876

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Trimix Injection with Doppler Ultrasound
Description: In case a large APA was identified, it will be dissected following the usual technique. Upon completion of the dissection, patients will have intracavernosal injection of 10 units (0.1 ml) of a Trimix administered (PGE1 10 mcg/ml, papaverine hydrochloride 30 mg/mL and phentolamine mesylate 1mg/mL.~Once the patient achieves a pharmacologic erection, the initial Doppler Ultrasound is completed, the accessory pudendal artery will be temporarily clamped to stop blood flow. After the artery is clamped, the Doppler Ultrasound will be repeated. We estimate an extension of the surgery no longer than 5 or 10 minutes in comparison to the usual operating time. Once the Doppler Ultrasound is completed, the clamp will be removed and the surgery continued in its usual fashion.
Study: NCT01157767

Intervention type: OTHER
Intervention: standardized regimen of exercises, including a warm-up period, ROM arm exercises, and strength training exercises.
Description: Module I is a group of arm movements. It consists of stretching exercises coordinated with breathing exercises to restore their physical mobility, range of motion and flexibility of shoulders. Module I is to be performed daily. In Module II the exercises are a series of copyrighted, sequential movements designed to put the body in proper alignment. It is a special series of muscle movements to help establish better body alignment, as well as increased strength and flexibility of one's arms, legs, and spine, each exercise is 4 repetitions. Module III is the walking and the resistance weight training program. The walking program is whole body exercise, multi-joint, weight-bearing, low impact and for beginners to advanced.
Study: NCT05439382

Intervention type: PROCEDURE
Intervention: Gingival recession regenerative surgery
Description: Bilaminar technique was performed by the same trained operator, opening a primary flap in correspondence of the recession site. Tissue was harvested from palatal donor site and grafted beneath the primary flap
Study: NCT03620162

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: M-M-R™ II
Description: M-M-R™ II (Measles, Mumps, and Rubella Virus Vaccine Live), given as background treatment via subcutaneous (SC) injection in the opposite limb to V114 and Prevnar 13™ administration.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: M-M-R™ II
Description: M-M-R™ II (Measles, Mumps, and Rubella Virus Vaccine Live), given as background treatment via subcutaneous (SC) injection in the opposite limb to V114 and Prevnar 13™ administration.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: M-M-R™ II
Description: M-M-R™ II (Measles, Mumps, and Rubella Virus Vaccine Live), given as background treatment via subcutaneous (SC) injection in the opposite limb to V114 and Prevnar 13™ administration.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: VARIVAX™
Description: VARIVAX™ Varicella Virus Vaccine Live, given as background treatment via SC injection in the opposite limb to V114 and Prevnar 13™ administration.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VARIVAX™
Description: VARIVAX™ Varicella Virus Vaccine Live, given as background treatment via SC injection in the opposite limb to V114 and Prevnar 13™ administration.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VARIVAX™
Description: VARIVAX™ Varicella Virus Vaccine Live, given as background treatment via SC injection in the opposite limb to V114 and Prevnar 13™ administration.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VARIVAX™
Description: VARIVAX™ Varicella Virus Vaccine Live, given as background treatment via SC injection in the opposite limb to V114 and Prevnar 13™ administration.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VARIVAX™
Description: VARIVAX™ Varicella Virus Vaccine Live, given as background treatment via SC injection in the opposite limb to V114 and Prevnar 13™ administration.
Study: NCT03528941

Intervention type: DRUG
Intervention: Lamivudine
Description: Patients who received lamivudine to prevent hepatitis B

Intervention type: OTHER
Intervention: No prophylaxis
Description: Patients who did not receive any prophylaxis to prevent hepatitis B
Study: NCT02411643

Intervention type: DRUG
Group type: OTHER
Intervention: topical calcipotriene 0.005% ointment
Description: Affected area will be treated twice daily for 3 months